OncoImmune

OncoImmune Overview

Founded 2000
Founded
Status Private
Latest Deal Type Later Stage VC
Latest Deal Amount $3M
Latest Deal Amount
Investors 5

OncoImmune General Information

Description

Developer of novel biopharmaceutical drugs intended to treat cancer and autoimmune disease. The company's offerings include recombinant fusion protein that targets a novel immune pathway checkpoint, enabling doctors to help with treating diseases targeting the immune system.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Primary Office
  • 9430 Key West Avenue
  • Suite 113
  • Rockville, MD 20850
  • United States

OncoImmune Timeline

2017201820192020
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoImmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 22-May-2020 $3M 0000 Completed Clinical Trials - General
3. Grant 30-Jul-2018 000.00 0000 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A) 12-Jan-2017 $15M $15M 0000 Completed Clinical Trials - Phase 2
1. Early Stage VC Completed Product Development

OncoImmune Cap Table

To view OncoImmune‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000 00.000000 00000.00 00000.00 00 00000.00 000

OncoImmune Executive Team (3)

Name Title Board Seat Contact Info
Martin Devenport Ph.D Chief Operating Officer
Yang Liu Ph.D Co-Founder, President, Chief Scientific Officer & Chairman
Pan Zheng MD Co-Founder, Senior Vice President, Chief Medical Officer and Board Member

OncoImmune Board Members (6)

To view OncoImmune‘s full board member team, request access »
Name Representing Role Since
Gary Fanger Ph.D Self Board Member 000 0000
Karen Liu Ph.D 3E Bioventures Capital Board Member 000 0000
Kun-Liang Guan Ph.D OncoImmune Co-Founder & Board Member 000 0000
Miao Hong Ph.D Self Board Member 000 0000
Ming You MD OncoImmune Co-Founder & Board Member 000 0000

OncoImmune Investors (5)

To view OncoImmune‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Cancer Institute Government 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
3E Bioventures Capital Venture Capital Minority 000 0000 000000 0
Ohio State University Technology Commercialization Office Accelerator/Incubator Minority 000 0000 000000 0

Ready to get started?

Request a free trial